Pathological staging in postneoadjuvant pancreatectomy for pancreatic cancer: implications for adjuvant therapy

Abstract Background It is unclear whether pathological staging is significant prognostically and can inform the delivery of adjuvant therapy after pancreatectomy preceded by neoadjuvant therapy. Methods This multicentre retrospective study included patients who underwent pancreatectomy for pancreati...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:British journal of surgery 2023-08, Vol.110 (8), p.973-982
Hauptverfasser: Maggino, Laura, Malleo, Giuseppe, Crippa, Stefano, Belfiori, Giulio, Bannone, Elisa, Lionetto, Gabriella, Gasparini, Giulia, Nobile, Sara, Luchini, Claudio, Mattiolo, Paola, Schiavo-Lena, Marco, Doglioni, Claudio, Scarpa, Aldo, Ferrone, Cristina, Bassi, Claudio, Fernández-del Castillo, Carlos, Falconi, Massimo, Salvia, Roberto
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page 982
container_issue 8
container_start_page 973
container_title British journal of surgery
container_volume 110
creator Maggino, Laura
Malleo, Giuseppe
Crippa, Stefano
Belfiori, Giulio
Bannone, Elisa
Lionetto, Gabriella
Gasparini, Giulia
Nobile, Sara
Luchini, Claudio
Mattiolo, Paola
Schiavo-Lena, Marco
Doglioni, Claudio
Scarpa, Aldo
Ferrone, Cristina
Bassi, Claudio
Fernández-del Castillo, Carlos
Falconi, Massimo
Salvia, Roberto
description Abstract Background It is unclear whether pathological staging is significant prognostically and can inform the delivery of adjuvant therapy after pancreatectomy preceded by neoadjuvant therapy. Methods This multicentre retrospective study included patients who underwent pancreatectomy for pancreatic ductal adenocarcinoma after neoadjuvant treatment at two Italian centres between 2013 and 2017. T and N status were assigned in accordance with the seventh and eighth editions of the AJCC staging system, as well as according to a modified system with T status definition combining extrapancreatic invasion and tumour size. Patients were then stratified by receipt of adjuvant therapy. Survival analysis and multivariable interaction analysis of adjuvant therapy with pathological parameters were performed. The results were validated in an external cohort from the USA. Results The developmental set consisted of 389 patients, with a median survival of 34.6 months. The modified staging system displayed the best prognostic stratification and the highest discrimination (C-index 0.763; 1-, 2- and 3-year time-dependent area under the curve (AUC) 0.746, 0.722, and 0.705; Uno’s AUC 0.710). Overall, 67.0 per cent of patients received adjuvant therapy. There was no survival difference by receipt of adjuvant therapy (35.0 versus 36.0 months; P = 0.772). After multivariable adjustment, interaction analysis suggested a benefit of adjuvant therapy for patients with nodal metastases or with tumours larger than 2 cm with extrapancreatic extension, regardless of nodal status. These results were confirmed in the external cohort of 216 patients. Conclusion Modified staging with a T status definition combining extrapancreatic invasion and tumour size is associated with better prognostic segregation after postneoadjuvant pancreatectomy. This system allows identification of patients who might benefit from adjuvant therapy. In this multi-institutional study of patients undergoing postneoadjuvant pancreatectomy, a modified staging system with T status definition combining extrapancreatic invasion and tumour size was associated with a more balanced patient distribution and better prognostic segregation. This system allows identification of a subgroup of patients who might benefit from adjuvant treatment.
doi_str_mv 10.1093/bjs/znad146
format Article
fullrecord <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_proquest_miscellaneous_2821643857</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><oup_id>10.1093/bjs/znad146</oup_id><sourcerecordid>2821643857</sourcerecordid><originalsourceid>FETCH-LOGICAL-c284t-bc864fe0004a51f1aece38e2eaaf1b2681053f282155def9ba53d0f0af8f7f7a3</originalsourceid><addsrcrecordid>eNo9kEtPwzAQhC0EoqVw4o5yQlwCfsSJyw1VvCQkOMA52jjr1lUSh9hBKr8eF0pPu9r5ZqUZQs4ZvWZ0Lm6qtb_57qBmWX5ApkzkMuUsV4dkSiktUia4mJAT79eUMkElPyYTUfA8avMpcW8QVq5xS6uhSXyApe2Wie2S3vnQoYN6PX5BF5IeOj0gBNTBtZvEuGF_sjrRccXhNrFt38RPwbrO_zJ7f1jhAP3mlBwZaDye7eaMfDzcvy-e0pfXx-fF3UuqucpCWmmVZwZjgAwkMwxQo1DIEcCwiueKUSkMV5xJWaOZVyBFTQ0Fo0xhChAzcvX3tx_c54g-lK31GpsGYqjRl1trngkli4he7NCxarEu-8G2MGzK_5IicPkHuLHfq4yW2_bL2H65a1_8AK6dedU</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2821643857</pqid></control><display><type>article</type><title>Pathological staging in postneoadjuvant pancreatectomy for pancreatic cancer: implications for adjuvant therapy</title><source>MEDLINE</source><source>Oxford University Press</source><creator>Maggino, Laura ; Malleo, Giuseppe ; Crippa, Stefano ; Belfiori, Giulio ; Bannone, Elisa ; Lionetto, Gabriella ; Gasparini, Giulia ; Nobile, Sara ; Luchini, Claudio ; Mattiolo, Paola ; Schiavo-Lena, Marco ; Doglioni, Claudio ; Scarpa, Aldo ; Ferrone, Cristina ; Bassi, Claudio ; Fernández-del Castillo, Carlos ; Falconi, Massimo ; Salvia, Roberto</creator><creatorcontrib>Maggino, Laura ; Malleo, Giuseppe ; Crippa, Stefano ; Belfiori, Giulio ; Bannone, Elisa ; Lionetto, Gabriella ; Gasparini, Giulia ; Nobile, Sara ; Luchini, Claudio ; Mattiolo, Paola ; Schiavo-Lena, Marco ; Doglioni, Claudio ; Scarpa, Aldo ; Ferrone, Cristina ; Bassi, Claudio ; Fernández-del Castillo, Carlos ; Falconi, Massimo ; Salvia, Roberto</creatorcontrib><description>Abstract Background It is unclear whether pathological staging is significant prognostically and can inform the delivery of adjuvant therapy after pancreatectomy preceded by neoadjuvant therapy. Methods This multicentre retrospective study included patients who underwent pancreatectomy for pancreatic ductal adenocarcinoma after neoadjuvant treatment at two Italian centres between 2013 and 2017. T and N status were assigned in accordance with the seventh and eighth editions of the AJCC staging system, as well as according to a modified system with T status definition combining extrapancreatic invasion and tumour size. Patients were then stratified by receipt of adjuvant therapy. Survival analysis and multivariable interaction analysis of adjuvant therapy with pathological parameters were performed. The results were validated in an external cohort from the USA. Results The developmental set consisted of 389 patients, with a median survival of 34.6 months. The modified staging system displayed the best prognostic stratification and the highest discrimination (C-index 0.763; 1-, 2- and 3-year time-dependent area under the curve (AUC) 0.746, 0.722, and 0.705; Uno’s AUC 0.710). Overall, 67.0 per cent of patients received adjuvant therapy. There was no survival difference by receipt of adjuvant therapy (35.0 versus 36.0 months; P = 0.772). After multivariable adjustment, interaction analysis suggested a benefit of adjuvant therapy for patients with nodal metastases or with tumours larger than 2 cm with extrapancreatic extension, regardless of nodal status. These results were confirmed in the external cohort of 216 patients. Conclusion Modified staging with a T status definition combining extrapancreatic invasion and tumour size is associated with better prognostic segregation after postneoadjuvant pancreatectomy. This system allows identification of patients who might benefit from adjuvant therapy. In this multi-institutional study of patients undergoing postneoadjuvant pancreatectomy, a modified staging system with T status definition combining extrapancreatic invasion and tumour size was associated with a more balanced patient distribution and better prognostic segregation. This system allows identification of a subgroup of patients who might benefit from adjuvant treatment.</description><identifier>ISSN: 0007-1323</identifier><identifier>EISSN: 1365-2168</identifier><identifier>DOI: 10.1093/bjs/znad146</identifier><identifier>PMID: 37260079</identifier><language>eng</language><publisher>US: Oxford University Press</publisher><subject>Carcinoma, Pancreatic Ductal - pathology ; Chemotherapy, Adjuvant ; Humans ; Neoadjuvant Therapy ; Neoplasm Staging ; Pancreatectomy - methods ; Pancreatic Neoplasms ; Pancreatic Neoplasms - pathology ; Prognosis ; Retrospective Studies</subject><ispartof>British journal of surgery, 2023-08, Vol.110 (8), p.973-982</ispartof><rights>The Author(s) 2023. Published by Oxford University Press on behalf of BJS Society Ltd. All rights reserved. For permissions, please e-mail: journals.permissions@oup.com 2023</rights><rights>The Author(s) 2023. Published by Oxford University Press on behalf of BJS Society Ltd. All rights reserved. For permissions, please e-mail: journals.permissions@oup.com.</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c284t-bc864fe0004a51f1aece38e2eaaf1b2681053f282155def9ba53d0f0af8f7f7a3</citedby><orcidid>0000-0001-5979-9396 ; 0000-0002-6248-4480 ; 0000-0001-5467-2628 ; 0000-0003-4901-4908 ; 0000-0003-4635-3680</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>315,781,785,1585,27929,27930</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/37260079$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Maggino, Laura</creatorcontrib><creatorcontrib>Malleo, Giuseppe</creatorcontrib><creatorcontrib>Crippa, Stefano</creatorcontrib><creatorcontrib>Belfiori, Giulio</creatorcontrib><creatorcontrib>Bannone, Elisa</creatorcontrib><creatorcontrib>Lionetto, Gabriella</creatorcontrib><creatorcontrib>Gasparini, Giulia</creatorcontrib><creatorcontrib>Nobile, Sara</creatorcontrib><creatorcontrib>Luchini, Claudio</creatorcontrib><creatorcontrib>Mattiolo, Paola</creatorcontrib><creatorcontrib>Schiavo-Lena, Marco</creatorcontrib><creatorcontrib>Doglioni, Claudio</creatorcontrib><creatorcontrib>Scarpa, Aldo</creatorcontrib><creatorcontrib>Ferrone, Cristina</creatorcontrib><creatorcontrib>Bassi, Claudio</creatorcontrib><creatorcontrib>Fernández-del Castillo, Carlos</creatorcontrib><creatorcontrib>Falconi, Massimo</creatorcontrib><creatorcontrib>Salvia, Roberto</creatorcontrib><title>Pathological staging in postneoadjuvant pancreatectomy for pancreatic cancer: implications for adjuvant therapy</title><title>British journal of surgery</title><addtitle>Br J Surg</addtitle><description>Abstract Background It is unclear whether pathological staging is significant prognostically and can inform the delivery of adjuvant therapy after pancreatectomy preceded by neoadjuvant therapy. Methods This multicentre retrospective study included patients who underwent pancreatectomy for pancreatic ductal adenocarcinoma after neoadjuvant treatment at two Italian centres between 2013 and 2017. T and N status were assigned in accordance with the seventh and eighth editions of the AJCC staging system, as well as according to a modified system with T status definition combining extrapancreatic invasion and tumour size. Patients were then stratified by receipt of adjuvant therapy. Survival analysis and multivariable interaction analysis of adjuvant therapy with pathological parameters were performed. The results were validated in an external cohort from the USA. Results The developmental set consisted of 389 patients, with a median survival of 34.6 months. The modified staging system displayed the best prognostic stratification and the highest discrimination (C-index 0.763; 1-, 2- and 3-year time-dependent area under the curve (AUC) 0.746, 0.722, and 0.705; Uno’s AUC 0.710). Overall, 67.0 per cent of patients received adjuvant therapy. There was no survival difference by receipt of adjuvant therapy (35.0 versus 36.0 months; P = 0.772). After multivariable adjustment, interaction analysis suggested a benefit of adjuvant therapy for patients with nodal metastases or with tumours larger than 2 cm with extrapancreatic extension, regardless of nodal status. These results were confirmed in the external cohort of 216 patients. Conclusion Modified staging with a T status definition combining extrapancreatic invasion and tumour size is associated with better prognostic segregation after postneoadjuvant pancreatectomy. This system allows identification of patients who might benefit from adjuvant therapy. In this multi-institutional study of patients undergoing postneoadjuvant pancreatectomy, a modified staging system with T status definition combining extrapancreatic invasion and tumour size was associated with a more balanced patient distribution and better prognostic segregation. This system allows identification of a subgroup of patients who might benefit from adjuvant treatment.</description><subject>Carcinoma, Pancreatic Ductal - pathology</subject><subject>Chemotherapy, Adjuvant</subject><subject>Humans</subject><subject>Neoadjuvant Therapy</subject><subject>Neoplasm Staging</subject><subject>Pancreatectomy - methods</subject><subject>Pancreatic Neoplasms</subject><subject>Pancreatic Neoplasms - pathology</subject><subject>Prognosis</subject><subject>Retrospective Studies</subject><issn>0007-1323</issn><issn>1365-2168</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2023</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNo9kEtPwzAQhC0EoqVw4o5yQlwCfsSJyw1VvCQkOMA52jjr1lUSh9hBKr8eF0pPu9r5ZqUZQs4ZvWZ0Lm6qtb_57qBmWX5ApkzkMuUsV4dkSiktUia4mJAT79eUMkElPyYTUfA8avMpcW8QVq5xS6uhSXyApe2Wie2S3vnQoYN6PX5BF5IeOj0gBNTBtZvEuGF_sjrRccXhNrFt38RPwbrO_zJ7f1jhAP3mlBwZaDye7eaMfDzcvy-e0pfXx-fF3UuqucpCWmmVZwZjgAwkMwxQo1DIEcCwiueKUSkMV5xJWaOZVyBFTQ0Fo0xhChAzcvX3tx_c54g-lK31GpsGYqjRl1trngkli4he7NCxarEu-8G2MGzK_5IicPkHuLHfq4yW2_bL2H65a1_8AK6dedU</recordid><startdate>20230801</startdate><enddate>20230801</enddate><creator>Maggino, Laura</creator><creator>Malleo, Giuseppe</creator><creator>Crippa, Stefano</creator><creator>Belfiori, Giulio</creator><creator>Bannone, Elisa</creator><creator>Lionetto, Gabriella</creator><creator>Gasparini, Giulia</creator><creator>Nobile, Sara</creator><creator>Luchini, Claudio</creator><creator>Mattiolo, Paola</creator><creator>Schiavo-Lena, Marco</creator><creator>Doglioni, Claudio</creator><creator>Scarpa, Aldo</creator><creator>Ferrone, Cristina</creator><creator>Bassi, Claudio</creator><creator>Fernández-del Castillo, Carlos</creator><creator>Falconi, Massimo</creator><creator>Salvia, Roberto</creator><general>Oxford University Press</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>7X8</scope><orcidid>https://orcid.org/0000-0001-5979-9396</orcidid><orcidid>https://orcid.org/0000-0002-6248-4480</orcidid><orcidid>https://orcid.org/0000-0001-5467-2628</orcidid><orcidid>https://orcid.org/0000-0003-4901-4908</orcidid><orcidid>https://orcid.org/0000-0003-4635-3680</orcidid></search><sort><creationdate>20230801</creationdate><title>Pathological staging in postneoadjuvant pancreatectomy for pancreatic cancer: implications for adjuvant therapy</title><author>Maggino, Laura ; Malleo, Giuseppe ; Crippa, Stefano ; Belfiori, Giulio ; Bannone, Elisa ; Lionetto, Gabriella ; Gasparini, Giulia ; Nobile, Sara ; Luchini, Claudio ; Mattiolo, Paola ; Schiavo-Lena, Marco ; Doglioni, Claudio ; Scarpa, Aldo ; Ferrone, Cristina ; Bassi, Claudio ; Fernández-del Castillo, Carlos ; Falconi, Massimo ; Salvia, Roberto</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c284t-bc864fe0004a51f1aece38e2eaaf1b2681053f282155def9ba53d0f0af8f7f7a3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2023</creationdate><topic>Carcinoma, Pancreatic Ductal - pathology</topic><topic>Chemotherapy, Adjuvant</topic><topic>Humans</topic><topic>Neoadjuvant Therapy</topic><topic>Neoplasm Staging</topic><topic>Pancreatectomy - methods</topic><topic>Pancreatic Neoplasms</topic><topic>Pancreatic Neoplasms - pathology</topic><topic>Prognosis</topic><topic>Retrospective Studies</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Maggino, Laura</creatorcontrib><creatorcontrib>Malleo, Giuseppe</creatorcontrib><creatorcontrib>Crippa, Stefano</creatorcontrib><creatorcontrib>Belfiori, Giulio</creatorcontrib><creatorcontrib>Bannone, Elisa</creatorcontrib><creatorcontrib>Lionetto, Gabriella</creatorcontrib><creatorcontrib>Gasparini, Giulia</creatorcontrib><creatorcontrib>Nobile, Sara</creatorcontrib><creatorcontrib>Luchini, Claudio</creatorcontrib><creatorcontrib>Mattiolo, Paola</creatorcontrib><creatorcontrib>Schiavo-Lena, Marco</creatorcontrib><creatorcontrib>Doglioni, Claudio</creatorcontrib><creatorcontrib>Scarpa, Aldo</creatorcontrib><creatorcontrib>Ferrone, Cristina</creatorcontrib><creatorcontrib>Bassi, Claudio</creatorcontrib><creatorcontrib>Fernández-del Castillo, Carlos</creatorcontrib><creatorcontrib>Falconi, Massimo</creatorcontrib><creatorcontrib>Salvia, Roberto</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>MEDLINE - Academic</collection><jtitle>British journal of surgery</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Maggino, Laura</au><au>Malleo, Giuseppe</au><au>Crippa, Stefano</au><au>Belfiori, Giulio</au><au>Bannone, Elisa</au><au>Lionetto, Gabriella</au><au>Gasparini, Giulia</au><au>Nobile, Sara</au><au>Luchini, Claudio</au><au>Mattiolo, Paola</au><au>Schiavo-Lena, Marco</au><au>Doglioni, Claudio</au><au>Scarpa, Aldo</au><au>Ferrone, Cristina</au><au>Bassi, Claudio</au><au>Fernández-del Castillo, Carlos</au><au>Falconi, Massimo</au><au>Salvia, Roberto</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Pathological staging in postneoadjuvant pancreatectomy for pancreatic cancer: implications for adjuvant therapy</atitle><jtitle>British journal of surgery</jtitle><addtitle>Br J Surg</addtitle><date>2023-08-01</date><risdate>2023</risdate><volume>110</volume><issue>8</issue><spage>973</spage><epage>982</epage><pages>973-982</pages><issn>0007-1323</issn><eissn>1365-2168</eissn><abstract>Abstract Background It is unclear whether pathological staging is significant prognostically and can inform the delivery of adjuvant therapy after pancreatectomy preceded by neoadjuvant therapy. Methods This multicentre retrospective study included patients who underwent pancreatectomy for pancreatic ductal adenocarcinoma after neoadjuvant treatment at two Italian centres between 2013 and 2017. T and N status were assigned in accordance with the seventh and eighth editions of the AJCC staging system, as well as according to a modified system with T status definition combining extrapancreatic invasion and tumour size. Patients were then stratified by receipt of adjuvant therapy. Survival analysis and multivariable interaction analysis of adjuvant therapy with pathological parameters were performed. The results were validated in an external cohort from the USA. Results The developmental set consisted of 389 patients, with a median survival of 34.6 months. The modified staging system displayed the best prognostic stratification and the highest discrimination (C-index 0.763; 1-, 2- and 3-year time-dependent area under the curve (AUC) 0.746, 0.722, and 0.705; Uno’s AUC 0.710). Overall, 67.0 per cent of patients received adjuvant therapy. There was no survival difference by receipt of adjuvant therapy (35.0 versus 36.0 months; P = 0.772). After multivariable adjustment, interaction analysis suggested a benefit of adjuvant therapy for patients with nodal metastases or with tumours larger than 2 cm with extrapancreatic extension, regardless of nodal status. These results were confirmed in the external cohort of 216 patients. Conclusion Modified staging with a T status definition combining extrapancreatic invasion and tumour size is associated with better prognostic segregation after postneoadjuvant pancreatectomy. This system allows identification of patients who might benefit from adjuvant therapy. In this multi-institutional study of patients undergoing postneoadjuvant pancreatectomy, a modified staging system with T status definition combining extrapancreatic invasion and tumour size was associated with a more balanced patient distribution and better prognostic segregation. This system allows identification of a subgroup of patients who might benefit from adjuvant treatment.</abstract><cop>US</cop><pub>Oxford University Press</pub><pmid>37260079</pmid><doi>10.1093/bjs/znad146</doi><tpages>10</tpages><orcidid>https://orcid.org/0000-0001-5979-9396</orcidid><orcidid>https://orcid.org/0000-0002-6248-4480</orcidid><orcidid>https://orcid.org/0000-0001-5467-2628</orcidid><orcidid>https://orcid.org/0000-0003-4901-4908</orcidid><orcidid>https://orcid.org/0000-0003-4635-3680</orcidid></addata></record>
fulltext fulltext
identifier ISSN: 0007-1323
ispartof British journal of surgery, 2023-08, Vol.110 (8), p.973-982
issn 0007-1323
1365-2168
language eng
recordid cdi_proquest_miscellaneous_2821643857
source MEDLINE; Oxford University Press
subjects Carcinoma, Pancreatic Ductal - pathology
Chemotherapy, Adjuvant
Humans
Neoadjuvant Therapy
Neoplasm Staging
Pancreatectomy - methods
Pancreatic Neoplasms
Pancreatic Neoplasms - pathology
Prognosis
Retrospective Studies
title Pathological staging in postneoadjuvant pancreatectomy for pancreatic cancer: implications for adjuvant therapy
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-13T17%3A13%3A12IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Pathological%20staging%20in%20postneoadjuvant%20pancreatectomy%20for%20pancreatic%20cancer:%20implications%20for%20adjuvant%20therapy&rft.jtitle=British%20journal%20of%20surgery&rft.au=Maggino,%20Laura&rft.date=2023-08-01&rft.volume=110&rft.issue=8&rft.spage=973&rft.epage=982&rft.pages=973-982&rft.issn=0007-1323&rft.eissn=1365-2168&rft_id=info:doi/10.1093/bjs/znad146&rft_dat=%3Cproquest_pubme%3E2821643857%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2821643857&rft_id=info:pmid/37260079&rft_oup_id=10.1093/bjs/znad146&rfr_iscdi=true